Genistein and phycocyanobilin may prevent hepatic fibrosis by suppressing proliferation and activation of hepatic stellate cells

Medical Hypotheses

Volumn 72, Issue 3, 2009, Pages 330-332

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BILIVERDIN; ESTROGEN; ESTROGEN RECEPTOR BETA; GENISTEIN; PHYCOCYANOBILIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN THERAPY; HUMAN; INHIBITION KINETICS; LIVER FIBROSIS; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; SPIRULINA; STELLATE CELL;

CELL PROLIFERATION; GENISTEIN; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; PHYCOBILINS; PHYCOCYANIN; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

SPIRULINA;

EID: 59249094905     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.07.045     Document Type: Article

References (38)

1. Di M.V., Lebray P., Myers R.P., Pannier E., Paradis V., Charlotte F., et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 40 (2004) 1426-1433
2. Codes L, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Parana R, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2006.
3. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 23 (2003) 63-69
4. Xu J.W., Gong J., Chang X.M., Luo J.Y., Dong L., Hao Z.M., et al. Estrogen reduces CCL4-induced liver fibrosis in rats. World J Gastroenterol 8 (2002) 883-887
5. Liu Q.H., Li D.G., Huang X., Zong C.H., Xu Q.F., and Lu H.M. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol 10 (2004) 1315-1320
6. Lu G., Shimizu I., Cui X., Itonaga M., Tamaki K., Fukuno H., et al. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci 74 (2004) 897-907
7. Zhou Y.J., Yin D.M., Chen H.S., Shi J.H., Sha B.X., and Wang X. Inhibitory effects of idoxifene on hepatic fibrosis in rats. Acta Pharmacol Sin 26 (2005) 581-586
8. Wu J., and Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35 (2000) 665-672
9. Shimizu I., Mizobuchi Y., Yasuda M., Shiba M., Ma Y.R., Horie T., et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 44 (1999) 127-136
10. Itagaki T., Shimizu I., Cheng X., Yuan Y., Oshio A., Tamaki K., et al. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 54 (2005) 1782-1789
11. Zhou Y., Shimizu I., Lu G., Itonaga M., Okamura Y., Shono M., et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun 286 (2001) 1059-1065
12. Morito K., Hirose T., Kinjo J., Hirakawa T., Okawa M., Nohara T., et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 24 (2001) 351-356
13. An J., Tzagarakis-Foster C., Scharschmidt T.C., Lomri N., and Leitman D.C. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276 (2001) 17808-17814
14. McCarty M.F. Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66 (2006) 1093-1114
15. Liu X.J., Yang L., Mao Y.Q., Wang Q., Huang M.H., Wang Y.P., et al. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J Gastroenterol 8 (2002) 739-745
16. Couse J.F., and Korach K.S. Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. Ann NY Acad Sci 948 (2001) 1-8
17. Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112 (2003) 1383-1394
18. Adachi T., Togashi H., Suzuki A., Kasai S., Ito J., Sugahara K., et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 41 (2005) 1272-1281
19. Kojima-Yuasa A., Umeda K., Ohkita T., Opare K.D., Nishiguchi S., and Matsui-Yuasa I. Role of reactive oxygen species in zinc deficiency-induced hepatic stellate cell activation. Free Radic Biol Med 39 (2005) 631-640
20. Zhan S.S., Jiang J.X., Wu J., Halsted C., Friedman S.L., Zern M.A., et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43 (2006) 435-443
21. Choi S.S., Sicklick J.K., Ma Q., Yang L., Huang J., Qi Y., et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology 44 (2006) 1267-1277
22. Sugimoto R., Enjoji M., Kohjima M., Tsuruta S., Fukushima M., Iwao M., et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 25 (2005) 1018-1026
23. Terry M.J., Maines M.D., and Lagarias J.C. Inactivation of phytochrome- and phycobiliprotein-chromophore precursors by rat liver biliverdin reductase. J Biol Chem 268 (1993) 26099-26106
24. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 19 (2005) 1890-1892
25. Matsumoto H., Ishikawa K., Itabe H., and Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 291 (2006) 21-28
26. Jiang F., Roberts S.J., Datla S., and Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 48 (2006) 950-957
27. Baranano D.E., Rao M., Ferris C.D., and Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99 (2002) 16093-16098
28. Bach F.H. Heme oxygenase-1 as a protective gene. Wien Klin Wochenschr 114 4 (2002) 1-3
29. Li L., Grenard P., Nhieu J.T., Julien B., Mallat A., Habib A., et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 125 (2003) 460-469
30. Li L., Julien B., Grenard P., Teixeira-Clerc F., Mallat A., and Lotersztajn S. Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts. J Hepatol 41 (2004) 407-413
31. Lee S.H., Seo G.S., Kim H.S., Woo S.W., Ko G., and Sohn D.H. 2', 4', 6'-Tris(methoxymethoxy) chalcone attenuates hepatic stellate cell proliferation by a heme oxygenase-dependent pathway. Biochem Pharmacol 72 (2006) 1322-1333
32. Tsui T.Y., Lau C.K., Ma J., Glockzin G., Obed A., Schlitt H.J., et al. Adeno-associated virus-mediated heme oxygenase-1 gene transfer suppresses the progression of micronodular cirrhosis in rats. World J Gastroenterol 12 (2006) 2016-2023
33. Melhem A., Stern M., Shibolet O., Israeli E., Ackerman Z., Pappo O., et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 39 (2005) 737-742
34. Berkson B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich) 94 3 (1999) 84-89
35. Wellington K., and Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15 (2001) 465-489
36. Lieber C.S. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 6 (2004) 60-65
37. Rivera C.A., Bradford B.U., Hunt K.J., Adachi Y., Schrum L.W., Koop D.R., et al. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 281 (2001) G200-G207
38. Wheeler M.D., Ikejema K., Enomoto N., Stacklewitz R.F., Seabra V., Zhong Z., et al. Glycine: a new anti-inflammatory immunonutrient. Cell Mol Life Sci 56 (1999) 843-856